Raymond James Financial
ALLO icon

Raymond James Financial’s Allogene Therapeutics ALLO Stock Holding History

Raymond James Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
+678,972
New +$1.49M ﹤0.01% 3747
2025
Q3 		– Sell
-45
Closed -$51 – 5011
2025
Q2 		$51 Buy
+45
New +$60 ﹤0.01% 6884

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Raymond James Financial's ALLO Position: Q2 2026 in Review

Raymond James Financial opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 678,972 shares worth $1.41M. The stake represents ﹤0.01% of the portfolio and ranks #3747 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in ALLO as recently as Q2 2025.

Raymond James Financial first reported a position in ALLO in Q2 2025 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Raymond James Financial held 678,972 shares of Allogene Therapeutics worth $1.41M as of Q2 2026.
  • Allogene Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3747 holding.
  • Raymond James Financial first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.